Scottish medical researcher
David A. Flockhart (1952–2015) was a Scottish medical researcher who was a leader in the field of personalised medicine.[1] He was especially known for his work on factors affecting the use of tamoxifen to treat breast cancer such as variability in the level of the CYP2D6 enzyme.[2][3]
- ^ Cite error: The named reference
E was invoked but never defined (see the help page).
- ^ Cite error: The named reference
EEN was invoked but never defined (see the help page).
- ^ Cite error: The named reference
IU was invoked but never defined (see the help page).